With regard to our manuscripts on the commercial saliva substitute, Oralbalance®—its formula has been changed
Letter to the editor
- 221 Downloads
KeywordsXylitol Oral Mucosa Hydroxyethyl Hematopoietic Cell Transplantation Neck Cancer Patient
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Conflict of interest
The authors have no conflicts of interest related to this letter.
- 1.Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM (2005) A double-blind, crossover study of Biotene Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care (Engl) 14:319–326. doi: 10.1111/j.1365-2354.2005.00587.x CrossRefGoogle Scholar
- 2.Sugiura Y, Soga Y, Tanimoto I, Kokeguchi S, Nishide S, Kono K, Takahashi K, Fujii N, Ishimaru F, Tanimoto M, Yamabe K, Tsutani S, Nishimura F, Takashiba S (2008) Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. Support Care Cancer 16:421–424. doi: 10.1007/s00520-007-0391-z PubMedCrossRefGoogle Scholar
- 3.Sugiura Y, Soga Y, Yamabe K, Tsutani S, Tanimoto I, Maeda H, Kokeguchi S, Fujii N, Ishimaru F, Tanimoto M, Nishimura F, Takashiba S (2010) Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation. Support Care Cancer 18:395–398. doi: 10.1007/s00520-009-0789-x PubMedCrossRefGoogle Scholar
© Springer-Verlag Berlin Heidelberg 2014